Efficacy and Safety of Antiviral Therapy

A topical collection in Viruses (ISSN 1999-4915). This collection belongs to the section "Viral Immunology, Vaccines, and Antivirals".

Viewed by 690

Editors


E-Mail Website
Collection Editor
Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy
Interests: HIV infection; antiretroviral therapy; HIV non infectious comorbidities; SARS-CoV-2; viral hepatitis in prison setting
Special Issues, Collections and Topics in MDPI journals

E-Mail
Collection Editor
Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy
Interests: HIV; antiviral treatment; HIV resistances; zoonotic diseases; SARS-CoV-2; COVID-19; bacterial infections
Special Issues, Collections and Topics in MDPI journals

E-Mail
Collection Editor
Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy
Interests: HIV infection; sexually transmitted infection; prevention; SARS-CoV-2 infection; viral infection; parasitology
Special Issues, Collections and Topics in MDPI journals

Topical Collection Information

Dear Colleagues,

During the last years, a great effort has been made to improve antiviral treatments. Also, new strategies are at the door.

SARS-CoV-2 has been a testing ground for new treatment strategies developed in a very short time frame, with apparently few mild adverse events reported. Additionally, antiretroviral therapy (ART) has embraced new molecules and new formulations, with the first injective ART already available in many countries for the treatment of HIV. Furthermore, interesting breakthroughs have been made in the field of hepatitis, creating the chance of hepatitis C eradication in the foreseeable future. Moreover, the first treatment for hepatitis delta has been introduced. Finally, regarding Herpesviridae, new strategies are being developed, including genomic editing techniques, and new drugs have already been introduced.

All these new treatment strategies and others that are not mentioned in the above paragraph have been shown to be extremely promising in clinical trials. However, further real-life studies are needed to better assess the efficacy, the burden of adverse events and their pathophysiological mechanisms.

Prof. Dr. Giordano Madeddu
Dr. Andrea De Vito
Dr. Agnese Colpani
Collection Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antiviral treatment
  • CMV
  • HBV
  • HCV
  • HDV
  • HIV
  • SARS-CoV-2
  • efficacy
  • adverse events
  • tolerability

Published Papers (1 paper)

2024

12 pages, 2519 KiB  
Article
Achievement of Primary Prevention Cardiometabolic Targets in Women with HIV: An Urgent Call to Action to Pursue Cardiovascular Health
by Maria Mazzitelli, Vincenzo Scaglione, Claudia Cozzolino, Marco Zuin, Cristina Putaggio, Beatrice Bragato, Eleonora Vania, Lolita Sasset, Davide Leoni, Vincenzo Baldo and Annamaria Cattelan
Viruses 2024, 16(4), 578; https://doi.org/10.3390/v16040578 - 09 Apr 2024
Viewed by 565
Abstract
Background: Cardiometabolic health has become crucial, especially for women with HIV (WWH). We assessed the achievement of targets for hypertension, dyslipidemia, and diabetes (H/Dy/DT) in primary prevention in a WWH cohort. Methods: Cross-sectional analysis including all WWH in our clinic, excluding those who [...] Read more.
Background: Cardiometabolic health has become crucial, especially for women with HIV (WWH). We assessed the achievement of targets for hypertension, dyslipidemia, and diabetes (H/Dy/DT) in primary prevention in a WWH cohort. Methods: Cross-sectional analysis including all WWH in our clinic, excluding those who had a myocardial infarction. H/Dy/DT achievement was assessed by both EACS guidelines and individual cardiovascular risk, CVR (measured by ESC calculator), using logistic regression to evaluate differences in H/Dy/DT achievement between migrant and Italian women. Results: We included 292 WWH, 55.5% Italian and 44.5% migrant women; the median age was 50 (IQR:42–58) years, 94.5% had undetectable HIV-RNA, 55.1% had a high level of education, 27.1% were smokers, and 19.2% did regularly physical exercise. Overall, 76%, 19%, and 5% of women presented a low, a high, and a very high CVR, respectively. Among Italians, 28.4% and 6.2% women presented a high and a very high CVR, respectively. Considering migrants, 7.7% and 3.8% women presented a high and a very high CVR, respectively. Overall, among migrant women, those with a high CVR were more likely to be not at target than those with a low risk (especially for LDL-c and blood pressure among people on treatment), despite the fact that we did not detect a statistically significant difference. By contrast, migrants were more likely to achieve glycemic targets than Italians (p = 0.032). Conclusions: H/Dy/DT target achievement is suboptimal, especially in migrants. A more aggressive pharmacological treatment, also assessing adherence to medical prescriptions, and promotion of healthy lifestyle should be urgently implemented, possibly redrawing the current model of care. Full article
Show Figures

Figure 1

Back to TopTop